In this interview, the son of an INR patient discusses his father’s response since starting treatment at the INR®. He explains how much this has meant to him and his family, and why he and his father have continued to fly to the INR each week for more than one year.
Individual results may vary. Continuing maintenance treatment is necessary to maintain the clinical response. Some patients do not respond. For further scientific information, please see:
- Perispinal etanercept: a new therapeutic paradigm in neurology. Edward Tobinick MD. Expert Review of Neurotherapeutics. 2010 Jun;10(6):985-1002.
- Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease. Edward Tobinick MD, H Gross MD. BMC Neurology. 2008 Jul 21;8:27.
Disclaimer: Individual results vary, not all patients respond. Continuing maintenance treatment may be necessary to maintain the clinical response. The method utilized for this indication is off-label. Please see the Terms of Use. Copyright 2015 INR PLLC, all rights reserved. Issued and pending U.S. and foreign patents, including, but not limited to, U.S. 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306, 8349323 and 8900583, all assigned to TACT IP, LLC; and Australian patent 758523.